Immunosuppression for the treatment of pulmonary hypertension in patients with systemic lupus erythematosus: A systematic review
- 4 May 2023
- journal article
- review article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 26 (6) , 1022-1028
Abstract
PurposeTo conduct a systematic review with meta-analysis to determine the effects of immunosuppression on Group 1 Pulmonary Arterial Hypertension in patients with systemic lupus erythematosus (SLE). MethodsWe searched Medline, Embase, Web of Science, , and Cochrane Central Register of Controlled Trials (CENTRAL) with a search strategy developed by a medical librarian. We included retrospective, cross-sectional, case-control, prospective studies, and randomized controlled trials (RCTs) in our analysis and only included studies that contained data for patients with SLE. We included any immunosuppressive agents (including but not limited to cyclophosphamide, glucocorticoids, mycophenolate mofetil, azathioprine, and rituximab) We assessed for risk of bias and certainty of evidence. Outcomes included hemodynamics (as measured by pulmonary arterial hypertension), functional status, 6 minute walk test (6MWT), quality of life, mortality, and serious adverse events. ResultsWe included three studies. One RCT and two single-arm interventional observational studies. The RCT had a high risk of bias whereas the two single-arm interventional studies were graded as fair quality. Meta-analysis could not be conducted because of insufficient data. The RCT showed significant improvements in hemodynamics (as measured by pulmonary arterial pressures) and functional status. One observational study showed improvements in hemodynamics, functional status, and 6MWT. There were insufficient data for serious adverse events, mortality, and quality of life. ConclusionsDespite a high prevalence and with a poor prognosis, there is a paucity of data for the role of immunosuppression in the treatment of Group 1 Pulmonary Arterial Hypertension in SLE. More high-quality studies are needed, especially to investigate serious adverse events and quality of life.Keywords
This publication has 19 references indexed in Scilit:
- Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysisAutoimmunity Reviews, 2016
- Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Prevalence and PredictorsThe Journal of Rheumatology, 2015
- Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational studyRheumatology, 2015
- Pulmonary hypertension in systemic lupus erythematosus: a systematic review and analysis of 642 cases in Chinese populationRheumatology International, 2012
- Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Current Status and Future DirectionJournal of Immunology Research, 2012
- REVEAL: a contemporary US pulmonary arterial hypertension registryEuropean Respiratory Review, 2012
- Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosusEuropean Respiratory Review, 2011
- Intensive Immunosuppressive Therapy Improves Pulmonary Hemodynamics and Long-Term Prognosis in Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue DiseaseCirculation Journal, 2011
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosusLupus, 2004